SLN
Silence TherapeuticsSLN
SLN
About: Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Employees: 116
0
Funds holding %
of 7,457 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
2.25% less ownership
Funds ownership: 17.71% [Q4 2024] → 15.46% (-2.25%) [Q1 2025]
11% less funds holding
Funds holding: 65 [Q4 2024] → 58 (-7) [Q1 2025]
25% less repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 24
43% less call options, than puts
Call options by funds: $4K | Put options by funds: $7K
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
64% less capital invested
Capital invested by funds: $168M [Q4 2024] → $60.6M (-$108M) [Q1 2025]
100% less funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 0 (-3) [Q1 2025]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$3
31%
downside
Avg. target
$33
646%
upside
High target
$75
1,616%
upside
5 analyst ratings
4 positive
80%
0 neutral
0%
1 negative
20%
Goldman Sachs Richard Law 45% 1-year accuracy 5 / 11 met price target | 31%downside $3 | Sell Maintained | 9 May 2025 |
Morgan Stanley Michael Ulz 32% 1-year accuracy 6 / 19 met price target | 472%upside $25 | Overweight Maintained | 9 May 2025 |
Chardan Capital Keay Nakae 16% 1-year accuracy 12 / 75 met price target | 701%upside $35 | Buy Maintained | 9 May 2025 |
HC Wainwright & Co. Patrick Trucchio 23% 1-year accuracy 39 / 170 met price target | 1,616%upside $75 | Buy Reiterated | 7 Mar 2025 |
BMO Capital Kostas Biliouris 7% 1-year accuracy 1 / 15 met price target | 472%upside $25 | Outperform Maintained | 4 Mar 2025 |
Financial journalist opinion
Neutral
Business Wire
1 week ago
Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the first quarter ended March 31, 2025, and reviewed recent business highlights. “Silence delivered another strong quarter focused on clinical and operational execution,” said Craig Tooman, President and Chief Executive Officer at Silence. “We remain focused on advancing enr.
Neutral
Business Wire
1 week ago
Silence Therapeutics Welcomes Tim McInerney to Board of Directors
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced the appointment of Tim McInerney to the Company's Board of Directors, effective immediately. Mr. McInerney will stand for re-appointment to the Silence Board at the Annual General Meeting (“AGM”) in June 2025. “We are thrilled to welcome Tim to the Silence Board,” said Iain Ross, Chairman of the Sil.
Neutral
Business Wire
2 months ago
Silence Therapeutics to Webcast Presentation at the Leerink Partners Global Healthcare Conference
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that management will present a company overview at the Leerink Partners Global Healthcare Conference on Wednesday, March 12th at 1:00 p.m. ET. The live webcast can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcast will be.
Positive
Zacks Investment Research
2 months ago
Silence Therapeutics (SLN) Upgraded to Buy: Here's What You Should Know
Silence Therapeutics (SLN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
Seeking Alpha
2 months ago
Silence Therapeutics plc (SLN) Q4 2024 Earnings Call Transcript
Silence Therapeutics plc (NASDAQ:SLN ) Q4 2024 Earnings Call February 27, 2025 8:00 AM ET Company Participants Gem Hopkins - Vice President, Investor Relations and Corporate Communications Craig Tooman - President and Chief Executive Officer Rhonda Hellums - Chief Financial Officer Steven Romano - Chief R&D Officer Conference Call Participants Mike Ulz - Morgan Stanley Kostas Biliouris - BMO Capital Markets Richard Law - Goldman Sachs Keay Nakae - Chardan Myles Minter - William Blair Gem Hopkins Good morning and good afternoon, everyone. Thank you for joining us today.
Neutral
Business Wire
2 months ago
Silence Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the full year ended December 31, 2024, and provided a business update. “2024 was marked by strong clinical execution and pipeline advancement, highlighting the broad potential of our mRNAi GOLD™ platform to silence disease causing genes,” said Craig Tooman, President and CEO.
Neutral
Business Wire
3 months ago
Silence Therapeutics to Report Fourth Quarter and Full Year 2024 Results on February 27, 2025
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that the Company will release its financial and business results for the fourth quarter and full year ended December 31, 2024, on Thursday, February 27, 2025. Management will host a conference call at 8:00 a.m. ET / 1:00 p.m. GMT that day to discuss the Company's financial results and provide a gene.
Positive
Benzinga
4 months ago
Top 3 Health Care Stocks That May Explode In Q4
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Neutral
Business Wire
5 months ago
Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (“Silence” or the “Company”) (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced additional results from the Phase 1 open label portion of the SANRECO study of divesiran, a siRNA targeting TMPRSS6, in patients with polycythemia vera (PV) were presented at the American Society of Hematology (ASH) Annual Meeting being held in San Diego, California. “Additional divesiran data pres.
Neutral
Business Wire
5 months ago
Silence Therapeutics to Participate in Fireside Chat at Piper Sandler 36th Annual Healthcare Conference
LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), a global clinical stage biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced the Company will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4th at 10:00 a.m. ET. The live webcast can be accessed via the Investors section of the Silence website at www.sile.
Charts implemented using Lightweight Charts™